Floatz logo

Capecitabine

Toxicity

National Cancer Institute, EgyptSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Toxicity cohort.

Asset / SponsorPhaseRating
ERIBULIN MONOMETHANESULFONATE
Oncologia Medica dell'Ospedale Fatebenefratelli
Phase 4BB
Irinotecan
Institut Cancerologie de l'Ouest
Phase 2BB
Eloxatin
National Cancer Institute, Egypt
Phase 2B
Carboplatin
Instituto Nacional de Cancerologia de Mexico
Phase 2B
FLUOROURACILUM
Institut Cancerologie de l'Ouest
Phase 2B

View all 10 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →